The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

MINI: We identified a set of genes, filaggrin (FLG), dystonin (DST), junction plakoglobin (JUP), and plakophilin-3 (PKP3), which are involved in cell-cell adhesions and associated with poor survival in melanomas. FLG, DST, and JUP support melanoma cell growth. The growth-promoting effects of JUP may be due to enhanced angiogenesis. OBJECTIVE To understand role of barrier molecules in melanomas. BACKGROUND We have reported poor patient survival and low immune infiltration of melanomas that overexpress a set of genes that include filaggrin (FLG), dystonin (DST), junction plakoglobin (JUP), and plakophilin-3 (PKP3), and are involved in cell-cell adhesions. We hypothesized that these associations are causal, either by interfering with immune cell infiltration or by enhancing melanoma cell growth. METHODS FLG and DST were knocked out by CRISPR/Cas9 in human DM93 and murine B16-F1 melanoma cells. PKP3 and JUP were overexpressed in murine B16-AAD and human VMM39 melanoma cells by lentiviral transduction. These cell lines were evaluated in vitro for cell proliferation and in vivo for tumor burden, immune composition, cytokine expression, and vascularity. RESULTS Immune infiltrates were not altered by these genes. FLG/DST knockout reduced proliferation of human DM93 melanoma in vitro, and decreased B16-F1 tumor burden in vivo. Overexpression of JUP, but not PKP3, in B16-AAD significantly increased tumor burden, increased VEGF-A, reduced IL-33, and enhanced vascularity. CONCLUSIONS FLG and DST support melanoma cell growth in vitro and in vivo. Growth effects of JUP were only evident in vivo, and may be mediated, in part, by enhancing angiogenesis. In addition, growth-promoting effects of FLG and DST in vitro suggest that these genes may also support melanoma cell proliferation through angiogenesis-independent pathways. These findings identify FLG, DST, and JUP as novel therapeutic targets whose down-regulation may provide clinical benefit to patients with melanoma.

[1]  V. Engelhard,et al.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors , 2019, Cancer Immunology, Immunotherapy.

[2]  Li'na Hu,et al.  PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer. , 2019, Biochemical and biophysical research communications.

[3]  Shumei Wang,et al.  Knock-down of filaggrin influences the mitogen-activated protein kinases signaling pathway in normal human epidermal keratinocytes. , 2018, Medecine sciences : M/S.

[4]  E. Puré,et al.  FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors , 2018, Cancer Immunology Research.

[5]  A. Pandey,et al.  A network map of IL-33 signaling pathway , 2018, Journal of Cell Communication and Signaling.

[6]  Camille Stephan-Otto Attolini,et al.  TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.

[7]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[8]  H. Kidoya,et al.  Plakoglobin maintains the integrity of vascular endothelial cell junctions and regulates VEGF-induced phosphorylation of VE-cadherin , 2017, Journal of biochemistry.

[9]  A. Giobbie-Hurder,et al.  Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes , 2017, Cancer Immunology Research.

[10]  F. Mattei,et al.  IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils , 2017, Oncoimmunology.

[11]  A. Gruber,et al.  TSLP is a direct trigger for T cell migration in filaggrin-deficient skin equivalents , 2017, Scientific Reports.

[12]  F. Marincola,et al.  Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk , 2016, Oncoimmunology.

[13]  F. Marincola,et al.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases , 2016, Cancer Immunology, Immunotherapy.

[14]  Xianguang Meng,et al.  Dysregulated function of normal human epidermal keratinocytes in the absence of filaggrin , 2016, Molecular medicine reports.

[15]  X. Ren,et al.  Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? , 2016, Cancer biology & medicine.

[16]  V. Engelhard,et al.  Effector lymphocyte-induced lymph node-like vasculature enables naïve T-cell entry into tumors and enhanced anti-tumor immunity , 2015, Nature Communications.

[17]  Elise Langenkamp,et al.  VEGF suppresses T‐lymphocyte infiltration in the tumor microenvironment through inhibition of NF‐κB‐induced endothelial activation , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Y. Qi,et al.  Tumoral Expression of IL-33 Inhibits Tumor Growth and Modifies the Tumor Microenvironment through CD8+ T and NK Cells , 2015, The Journal of Immunology.

[19]  S. Kežić,et al.  Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. , 2014, The Journal of investigative dermatology.

[20]  J. Waschke,et al.  Plakoglobin but not desmoplakin regulates keratinocyte cohesion via modulation of p38MAPK signaling. , 2014, The Journal of investigative dermatology.

[21]  D. Hohl,et al.  The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the ‘fused genes’ family , 2012, Experimental dermatology.

[22]  H. Mizuno,et al.  Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. , 2012, The Journal of allergy and clinical immunology.

[23]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[24]  Henrik Schmidt,et al.  A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma , 2011, Journal of Translational Medicine.

[25]  S. Dalal,et al.  E-cadherin and plakoglobin recruit plakophilin3 to the cell border to initiate desmosome assembly , 2011, Cellular and Molecular Life Sciences.

[26]  M. Tsujikawa,et al.  Tumor-associated calcium signal transducer 2 is required for the proper subcellular localization of claudin 1 and 7: implications in the pathogenesis of gelatinous drop-like corneal dystrophy. , 2010, The American journal of pathology.

[27]  M. Mildner,et al.  Knockdown of filaggrin impairs diffusion barrier function and increases UV sensitivity in a human skin model. , 2010, The Journal of investigative dermatology.

[28]  Jaeyoung Ko,et al.  MAP17 is associated with the T‐helper cell cytokine‐induced down‐regulation of filaggrin transcription in human keratinocytes , 2010, Experimental dermatology.

[29]  V. Vacic,et al.  Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival , 2009, Proceedings of the National Academy of Sciences.

[30]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[31]  J. Pollheimer,et al.  Vascular Biology , Atherosclerosis and Endothelium Biology Nuclear Interleukin-33 Is Generally Expressed in Resting Endothelium but Rapidly Lost upon Angiogenic or Proinflammatory Activation , 2010 .

[32]  J. Uitto,et al.  Interferon‐γ down‐regulates expression of the 230‐kDa bullous pemphigoid antigen gene (BPAG1) in epidermal keratinocytes via novel chimeric sequences of ISRE and GAS , 2006, Experimental dermatology.

[33]  K. G. Young,et al.  Bpag1 localization to actin filaments and to the nucleus is regulated by its N-terminus , 2003, Journal of Cell Science.

[34]  P. Hu,et al.  Keratinocyte adherens junctions initiate nuclear signaling by translocation of plakoglobin from the membrane to the nucleus. , 2003, The Journal of investigative dermatology.

[35]  F. van Roy,et al.  Defining desmosomal plakophilin-3 interactions , 2003, The Journal of cell biology.

[36]  R. Presland,et al.  Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. , 2002, The Journal of investigative dermatology.

[37]  M. Kuechle,et al.  Regulated expression of human filaggrin in keratinocytes results in cytoskeletal disruption, loss of cell-cell adhesion, and cell cycle arrest. , 2001, Experimental cell research.

[38]  V. Engelhard,et al.  Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice1 , 2001, The Journal of Immunology.

[39]  M. Kuechle,et al.  Inducible expression of filaggrin increases keratinocyte susceptibility to apoptotic cell death , 2000, Cell Death and Differentiation.

[40]  M. Pasdar,et al.  Plakoglobin Regulates the Expression of the Anti-apoptotic Protein BCL-2* , 2000, The Journal of Biological Chemistry.

[41]  A. Ciechanover,et al.  Differential interaction of plakoglobin and β-catenin with the ubiquitin-proteasome system , 2000, Oncogene.

[42]  F. van Roy,et al.  Plakophilin-3, a novel armadillo-like protein present in nuclei and desmosomes of epithelial cells. , 1999, Journal of cell science.

[43]  Benjamin Geiger,et al.  Differential Nuclear Translocation and Transactivation Potential of β-Catenin and Plakoglobin , 1998, The Journal of cell biology.

[44]  V. Engelhard,et al.  Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. , 1996, Journal of immunology.

[45]  Z. Šidák.  Rectangular Confidence Regions for the Means of Multivariate Normal Distributions , 1967 .

[46]  S. Dalal,et al.  Plakophilin3 increases desmosome assembly, size and stability by increasing expression of desmocollin2. , 2018, Biochemical and biophysical research communications.

[47]  E. Tartour,et al.  Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.

[48]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[49]  S. Holm.  A Simple Sequentially Rejective Multiple Test Procedure , 1979 .